discussions with industry experts

Most recently a director at Willis Towers Watson, Coleman led business and product development, actuarial support, and distribution strategy for the fixed, indexed and variable annuity markets. He previously co-founded the Ideal Producers Group, where he spearheaded the actuarial department and led product innovation, design and marketing.

“At a time of increased distribution aggregation in the life and annuity markets, the integration of product development and distribution is a key business accelerator,” Coleman said in a news release. “Quality and insightful product development turns insurer relationships into long-lasting partnerships and maximizes the value delivered up and down the vertical.” value chain. Hopefully, we make their lives easier and make them more efficient at what they do.”

Future growth

That doesn’t mean AmeriLife isn’t interested in proprietary life and annuity products of its own. That’s where Coleman comes in.

That kind of return on investment is necessary for AmeriLife now that it is in the hands of private equity firms. Reservoir Capital Group and Black Diamond Capital Partners acquired AmeriLife in 2007, and sold it in 2015 to J.C. Flowers for less than $500 million, Barron’s reported.

A third PE firm, Thomas H. Lee Partners, acquired AmeriLife in 2020 in a reported deal that exceeded $1 billion.

Conjecture remains afloat that one or more of the aggressive IMOs will go public at some point. Perry doesn’t rule it out but said that isn’t the plan right now.

“We don’t think about the exit. We think about running the business and building a great company,” he said. “There are a number of paths that we could go. Now is not the time, but we’ll make the determination of what’s the best way to maximize value for shareholders. Absolutely.”

InsuranceNewsNet

Senior Editor John Hilton has covered business and other beats in more than 20 years of daily journalism. John may be reached at john.hilton@innfeedback. com. Follow him on Twitter @INNJohnH.

Like this article or any other?

Take